Vedanta Biosciences, Inc.

Vedanta Biosciences, Inc. is a biotechnology startup based in the United States, pioneering the rational design of drugs made of defined bacteria consortia essential to the gut ecosystem. Their focus lies in understanding the critical functions of the human microbiome, which includes aiding in immune system development, nutrient manufacturing, and energy extraction from the diet. Their innovative approach is timely, as the alteration of the human microbiome is increasingly recognized as a key factor in various diseases, such as autoimmune, metabolic, and infectious conditions. The startup was founded in 2010 and has recently secured a $3.90M grant investment from CARB-X at 30 April 2024. Vedanta's unique value proposition stems from their development of a novel class of therapies that modulate the interaction pathways between the human microbiome and the host immune system. This initiative is backed by co-founders with expertise in immunology and microbiology, alongside the support of PureTech Health. In summary, Vedanta Biosciences, Inc. stands at the forefront of biotechnology, leveraging innovative approaches to decipher the language of the human microbiome and develop therapeutic solutions. Their recent collaboration with CARB-X marks a significant milestone in their journey towards addressing critical health challenges through their pioneering research and rational drug design.